Ad is loading...
RNWFX
Price
$80.56
Change
-$0.79 (-0.97%)
Updated
Nov 15 closing price
TEOJX
Price
$7.93
Change
-$0.01 (-0.13%)
Updated
Nov 15 closing price
Ad is loading...

RNWFX vs TEOJX

Header iconRNWFX vs TEOJX Comparison
Open Charts RNWFX vs TEOJXBanner chart's image
American Funds New World R5
Price$80.56
Change-$0.79 (-0.97%)
VolumeN/A
CapitalizationN/A
Transamerica Emerging Markets Eq I2
Price$7.93
Change-$0.01 (-0.13%)
VolumeN/A
CapitalizationN/A
RNWFX vs TEOJX Comparison Chart
Loading...
View a ticker or compare two or three
VS
RNWFX vs. TEOJX commentary
Nov 18, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is RNWFX is a Buy and TEOJX is a Hold.

FUNDAMENTALS
Fundamentals
RNWFX has more cash in the bank: 60.9B vs. TEOJX (123M). TEOJX pays higher dividends than RNWFX: TEOJX (2.78) vs RNWFX (1.51). RNWFX was incepted earlier than TEOJX: RNWFX (23 years) vs TEOJX (5 years). TEOJX is a more actively managed with annual turnover of: 68.00 vs. RNWFX (32.00). TEOJX has a lower initial minimum investment than RNWFX: TEOJX (0) vs RNWFX (250). RNWFX annual gain was more profitable for investors over the last year : 11.54 vs. TEOJX (9.86).
RNWFXTEOJXRNWFX / TEOJX
Total Expense RatioN/AN/A-
Annual Report Gross Expense RatioN/AN/A-
Fund Existence23 years5 years-
Gain YTD7.0996.873103%
Front LoadN/AN/A-
Min. Initial Investment2500-
Min. Initial Investment IRAN/AN/A-
Net Assets60.9B123M49,512%
Annual Yield % from dividends1.512.7854%
Returns for 1 year11.549.86117%
Returns for 3 years-14.55-28.8850%
Returns for 5 years17.17N/A-
Returns for 10 years41.00N/A-
View a ticker or compare two or three
Ad is loading...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
VRNA35.660.29
+0.82%
Verona Pharma plc
BURL268.94-0.65
-0.24%
Burlington Stores
RCMT22.25-0.38
-1.68%
RCM Technologies
SNTI2.15-0.18
-7.73%
Senti Biosciences Inc.
CATX7.88-1.04
-11.66%
Perspective Therapeutics